An Adaptive Design, Phase 1, Open-label Study to Investigate Receptor Occupancy in Brain After Single Oral Doses of LY3857210 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]-LY3818850 in Healthy Participants
Latest Information Update: 03 Mar 2023
At a glance
- Drugs LY 3857210 (Primary)
- Indications Back pain; Diabetic nephropathies; Neuropathic pain; Pain
- Focus Pharmacodynamics
- Sponsors Eli Lilly and Company
Most Recent Events
- 28 Feb 2023 Status changed from recruiting to completed.
- 13 Feb 2023 Planned End Date changed from 23 Dec 2022 to 10 Mar 2023.
- 13 Feb 2023 Planned primary completion date changed from 23 Dec 2022 to 10 Mar 2023.